# CBLC

Source: https://onco.cc/targets/cblc/  
OnCo record `cblc` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.

## Summary

Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Olaparib.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: Cbl proto-oncogene C; E3 ubiquitin-protein ligase CBL-C; CBL-3; CBL-SL; RNF57
- Tags: cancer-genes-wave
- Symbol: CBLC
- Class: enzyme
- Biology: Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR. Isoform 1, but not isoform 2, inhibits EGF stimulated MAPK1 activation. Promotes ubiquitination of SRC phosphorylated at 'Tyr-419'. In collaboration with CD2AP may act as regulatory checkpoint for Ret signalling by modulating the rate of RET degradation after ligand activation; CD2AP converts it from an inhibitor to a promoter of RET degradation; the function limits the potency of GDNF on neuronal survival. Locus 19q13.32 (HGNC).
- Where found: Breast cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:15961: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15961
- UniProt Q9ULV8: https://www.uniprot.org/uniprotkb/Q9ULV8/entry
- NCBI Gene 23624: https://www.ncbi.nlm.nih.gov/gene/23624
- Ensembl ENSG00000142273: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142273

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)

---
JSON: https://onco.cc/api/v1/entities/cblc.json